{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T22:29:13Z","timestamp":1787524153678,"version":"build-2736575974"},"reference-count":60,"publisher":"Aging and Disease","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2025]]},"DOI":"10.14336\/ad.2024.0323","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T14:39:46Z","timestamp":1717771186000},"page":"619","source":"Crossref","is-referenced-by-count":10,"title":["Neuroanatomical Signature of the Transition from Normal Cognition to MCI in Parkinson's Disease"],"prefix":"10.14336","volume":"16","author":[{"given":"Iman","family":"Beheshti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarrad","family":"Perron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2024.0323-1","doi-asserted-by":"crossref","unstructured":"Adrissi J, Fleisher J (2022). Moving the dial toward equity in Parkinson\u2019s disease clinical research: a review of current literature and future directions in diversifying PD clinical trial participation. Current neurology and neuroscience reports, 22:475-483.","DOI":"10.1007\/s11910-022-01212-8"},{"key":"key-10.14336\/AD.2024.0323-2","doi-asserted-by":"crossref","unstructured":"Sveinbjornsdottir S (2016). The clinical symptoms of Parkinson's disease. J Neurochem, 139 Suppl 1:318-324.","DOI":"10.1111\/jnc.13691"},{"key":"key-10.14336\/AD.2024.0323-3","doi-asserted-by":"crossref","unstructured":"Lee Y-g, Park M, Jeong SH, Baik K, Kang S, Yoon SH, et al. (2023). Association of neuropsychiatric symptom profiles with cognitive decline in patients with Parkinson disease and mild cognitive impairment. Neurology, 101:e1186-e1195.","DOI":"10.1212\/WNL.0000000000207623"},{"key":"key-10.14336\/AD.2024.0323-4","doi-asserted-by":"crossref","unstructured":"Myers PS, O'Donnell JL, Jackson JJ, Lessov-Schlaggar CN, Miller RL, Foster ER, et al. (2022). Proteinopathy and longitudinal cognitive decline in Parkinson disease. Neurology, 99:e66-e76.","DOI":"10.1212\/WNL.0000000000200344"},{"key":"key-10.14336\/AD.2024.0323-5","doi-asserted-by":"crossref","unstructured":"Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. (2017). Cognitive decline in Parkinson disease. Nat Rev Neurol, 13:217-231.","DOI":"10.1038\/nrneurol.2017.27"},{"key":"key-10.14336\/AD.2024.0323-6","doi-asserted-by":"crossref","unstructured":"Svenningsson P, Westman E, Ballard C, Aarsland D (2012). Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol, 11:697-707.","DOI":"10.1016\/S1474-4422(12)70152-7"},{"key":"key-10.14336\/AD.2024.0323-7","doi-asserted-by":"crossref","unstructured":"Kim R, Choi S, Byun K, Kang N, Suh YJ, Jun J-S, et al. (2023). Association of Early Weight Change With Cognitive Decline in Patients With Parkinson Disease. Neurology, 100:e232-e241.","DOI":"10.1212\/WNL.0000000000201404"},{"key":"key-10.14336\/AD.2024.0323-8","doi-asserted-by":"crossref","unstructured":"Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, et al. (2021). Parkinson disease-associated cognitive impairment. Nature Reviews Disease Primers, 7:47.","DOI":"10.1038\/s41572-021-00280-3"},{"key":"key-10.14336\/AD.2024.0323-9","doi-asserted-by":"crossref","unstructured":"Emre M (2003). Dementia associated with Parkinson's disease. Lancet Neurol, 2:229-237.","DOI":"10.1016\/S1474-4422(03)00351-X"},{"key":"key-10.14336\/AD.2024.0323-10","doi-asserted-by":"crossref","unstructured":"Mattila PM, R\u00f6ytt\u00e4 M, L\u00f6nnberg P, Marjam\u00e4ki P, Helenius H, Rinne JO (2001). Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol, 102:160-166.","DOI":"10.1007\/s004010100372"},{"key":"key-10.14336\/AD.2024.0323-11","doi-asserted-by":"crossref","unstructured":"Reich MM, Hsu J, Ferguson M, Schaper FL, Joutsa J, Roothans J, et al. (2022). A brain network for deep brain stimulation induced cognitive decline in Parkinson\u2019s disease. Brain, 145:1410-1421.","DOI":"10.1093\/brain\/awac012"},{"key":"key-10.14336\/AD.2024.0323-12","doi-asserted-by":"crossref","unstructured":"Wang H, Atik A, Stewart T, Ginghina C, Aro P, Kerr KF, et al. (2018). Plasma \u03b1-synuclein and cognitive impairment in the Parkinson's associated risk syndrome: a pilot study. Neurobiology of disease, 116:53-59.","DOI":"10.1016\/j.nbd.2018.04.015"},{"key":"key-10.14336\/AD.2024.0323-13","doi-asserted-by":"crossref","unstructured":"Johansson ME, Toni I, Kessels RP, Bloem BR, Helmich RC (2023). Clinical severity in Parkinson's disease is determined by decline in cortical compensation. medRxiv:2023.2004. 2016.23288636.","DOI":"10.1101\/2023.04.16.23288636"},{"key":"key-10.14336\/AD.2024.0323-14","doi-asserted-by":"crossref","unstructured":"Mak E, Zhou J, Tan LC, Au WL, Sitoh YY, Kandiah N (2014). Cognitive deficits in mild Parkinson's disease are associated with distinct areas of grey matter atrophy. J Neurol Neurosurg Psychiatry, 85:576-580.","DOI":"10.1136\/jnnp-2013-305805"},{"key":"key-10.14336\/AD.2024.0323-15","doi-asserted-by":"crossref","unstructured":"Wood DA, Kafiabadi S, Al Busaidi A, Guilhem E, Montvila A, Lynch J, et al. (2022). Accurate brain-age models for routine clinical MRI examinations. Neuroimage, 249:118871.","DOI":"10.1016\/j.neuroimage.2022.118871"},{"key":"key-10.14336\/AD.2024.0323-16","doi-asserted-by":"crossref","unstructured":"Sone D, Beheshti I (2022). Neuroimaging-based brain age estimation: a promising personalized biomarker in neuropsychiatry. Journal of Personalized Medicine, 12:1850.","DOI":"10.3390\/jpm12111850"},{"key":"key-10.14336\/AD.2024.0323-17","unstructured":"Mishra S, Beheshti I, Khanna P (2021). A Review of Neuroimaging-driven Brain Age Estimation for identification of Brain Disorders and Health Conditions. IEEE Reviews in Biomedical Engineering."},{"key":"key-10.14336\/AD.2024.0323-18","unstructured":"Mishra S, Beheshti I, Khanna P (2021). A Review of Neuroimaging-driven Brain Age Estimation for identification of Brain Disorders and Health Conditions. IEEE Rev Biomed Eng, PP."},{"key":"key-10.14336\/AD.2024.0323-19","doi-asserted-by":"crossref","unstructured":"Busby N, Wilmskoetter J, Gleichgerrcht E, Rorden C, Roth R, Newman-Norlund R, et al. (2023). Advanced brain age and chronic poststroke aphasia severity. Neurology, 100:e1166-e1176.","DOI":"10.1212\/WNL.0000000000201693"},{"key":"key-10.14336\/AD.2024.0323-20","doi-asserted-by":"crossref","unstructured":"Eickhoff CR, Hoffstaedter F, Caspers J, Reetz K, Mathys C, Dogan I, et al. (2021). Advanced brain ageing in Parkinson\u2019s disease is related to disease duration and individual impairment. Brain communications, 3:fcab191.","DOI":"10.1093\/braincomms\/fcab191"},{"key":"key-10.14336\/AD.2024.0323-21","doi-asserted-by":"crossref","unstructured":"Beheshti I, Mishra S, Sone D, Khanna P, Matsuda H (2020). T1-weighted MRI-driven brain age estimation in Alzheimer\u2019s disease and Parkinson\u2019s disease. Aging and disease, 11:618.","DOI":"10.14336\/AD.2019.0617"},{"key":"key-10.14336\/AD.2024.0323-22","doi-asserted-by":"crossref","unstructured":"Litvan I, Goldman JG, Tr\u00f6ster AI, Schmand BA, Weintraub D, Petersen RC, et al. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Movement disorders, 27:349-356.","DOI":"10.1002\/mds.24893"},{"key":"key-10.14336\/AD.2024.0323-23","doi-asserted-by":"crossref","unstructured":"Farokhian F, Beheshti I, Sone D, Matsuda H (2017). Comparing CAT12 and VBM8 for Detecting Brain Morphological Abnormalities in Temporal Lobe Epilepsy. Front Neurol, 8:428.","DOI":"10.3389\/fneur.2017.00428"},{"key":"key-10.14336\/AD.2024.0323-24","doi-asserted-by":"crossref","unstructured":"Desikan RS, S\u00e9gonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. (2006). An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage, 31:968-980.","DOI":"10.1016\/j.neuroimage.2006.01.021"},{"key":"key-10.14336\/AD.2024.0323-25","unstructured":"Cole JH, Underwood J, Caan MW, De Francesco D, van Zoest RA, Leech R, et al. (2017). Increased brain-predicted aging in treated HIV disease. Neurology, 88:1349-1357."},{"key":"key-10.14336\/AD.2024.0323-26","doi-asserted-by":"crossref","unstructured":"Beheshti I, Booth S, Ko JH (2024). Differences in brain aging between sexes in Parkinson\u2019s disease. npj Parkinson's Disease, 10:35.","DOI":"10.1038\/s41531-024-00646-w"},{"key":"key-10.14336\/AD.2024.0323-27","doi-asserted-by":"crossref","unstructured":"Beheshti I, Nugent S, Potvin O, Duchesne S (2019). Bias-adjustment in neuroimaging-based brain age frameworks: A robust scheme. Neuroimage Clin, 24:102063.","DOI":"10.1016\/j.nicl.2019.102063"},{"key":"key-10.14336\/AD.2024.0323-28","doi-asserted-by":"crossref","unstructured":"Harvey J, Reijnders RA, Cavill R, Duits A, K\u00f6hler S, Eijssen L, et al. (2022). Machine learning-based prediction of cognitive outcomes in de novo Parkinson\u2019s disease. npj Parkinson's Disease, 8:150.","DOI":"10.1038\/s41531-022-00409-5"},{"key":"key-10.14336\/AD.2024.0323-29","doi-asserted-by":"crossref","unstructured":"Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P (2014). The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. Movement Disorders, 29:1035-1043.","DOI":"10.1002\/mds.25919"},{"key":"key-10.14336\/AD.2024.0323-30","doi-asserted-by":"crossref","unstructured":"Cole JH, Ritchie SJ, Bastin ME, Vald\u00e9s Hern\u00e1ndez MC, Mu\u00f1oz Maniega S, Royle N, et al. (2018). Brain age predicts mortality. Mol Psychiatry, 23:1385-1392.","DOI":"10.1038\/mp.2017.62"},{"key":"key-10.14336\/AD.2024.0323-31","doi-asserted-by":"crossref","unstructured":"Sone D, Beheshti I, Maikusa N, Ota M, Kimura Y, Sato N, et al. (2021). Neuroimaging-based brain-age prediction in diverse forms of epilepsy: a signature of psychosis and beyond. Mol Psychiatry, 26:825-834.","DOI":"10.1038\/s41380-019-0446-9"},{"key":"key-10.14336\/AD.2024.0323-32","doi-asserted-by":"crossref","unstructured":"Gonzalez-Redondo R, Garc\u00eda-Garc\u00eda D, Clavero P, Gasca-Salas C, Garc\u00eda-Eulate R, Zubieta JL, et al. (2014). Grey matter hypometabolism and atrophy in Parkinson\u2019s disease with cognitive impairment: a two-step process. Brain, 137:2356-2367.","DOI":"10.1093\/brain\/awu159"},{"key":"key-10.14336\/AD.2024.0323-33","doi-asserted-by":"crossref","unstructured":"Ko JH, Katako A, Aljuaid M, Goertzen AL, Borys A, Hobson DE, et al. (2017). Distinct brain metabolic patterns separately associated with cognition, motor function, and aging in Parkinson's disease dementia. Neurobiology of Aging, 60:81-91.","DOI":"10.1016\/j.neurobiolaging.2017.08.020"},{"key":"key-10.14336\/AD.2024.0323-34","doi-asserted-by":"crossref","unstructured":"Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D (2007). Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage, 34:714-723.","DOI":"10.1016\/j.neuroimage.2006.09.003"},{"key":"key-10.14336\/AD.2024.0323-35","doi-asserted-by":"crossref","unstructured":"Pereira JB, Hall S, Jalakas M, Grothe MJ, Strandberg O, Stomrud E, et al. (2020). Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. Neurobiology of disease, 139:104831.","DOI":"10.1016\/j.nbd.2020.104831"},{"key":"key-10.14336\/AD.2024.0323-36","doi-asserted-by":"crossref","unstructured":"Ray NJ, Bradburn S, Murgatroyd C, Toseeb U, Mir P, Kountouriotis GK, et al. (2018). In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson\u2019s disease. Brain, 141:165-176.","DOI":"10.1093\/brain\/awx310"},{"key":"key-10.14336\/AD.2024.0323-37","doi-asserted-by":"crossref","unstructured":"Weintraub D, Dietz N, Duda JE, Wolk DA, Doshi J, Xie SX, et al. (2012). Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain, 135:170-180.","DOI":"10.1093\/brain\/awr277"},{"key":"key-10.14336\/AD.2024.0323-38","doi-asserted-by":"crossref","unstructured":"Li L, Ji B, Zhao T, Cui X, Chen J, Wang Z (2022). The structural changes of gray matter in Parkinson disease patients with mild cognitive impairments. Plos one, 17:e0269787.","DOI":"10.1371\/journal.pone.0269787"},{"key":"key-10.14336\/AD.2024.0323-39","doi-asserted-by":"crossref","unstructured":"Zhong Y, Liu H, Liu G, Zhao L, Dai C, Liang Y, et al. (2022). A review on pathology, mechanism, and therapy for cerebellum and tremor in Parkinson\u2019s disease. npj Parkinson's Disease, 8:82.","DOI":"10.1038\/s41531-022-00347-2"},{"key":"key-10.14336\/AD.2024.0323-40","doi-asserted-by":"crossref","unstructured":"Wu T, Hallett M (2013). The cerebellum in Parkinson\u2019s disease. Brain, 136:696-709.","DOI":"10.1093\/brain\/aws360"},{"key":"key-10.14336\/AD.2024.0323-41","doi-asserted-by":"crossref","unstructured":"Li T, Le W, Jankovic J (2023). Linking the cerebellum to Parkinson disease: an update. Nature Reviews Neurology, 19:645-654.","DOI":"10.1038\/s41582-023-00874-3"},{"key":"key-10.14336\/AD.2024.0323-42","doi-asserted-by":"crossref","unstructured":"Pereira JB, Junqu\u00e9 C, Mart\u00ed MJ, Ramirez-Ruiz B, Bartres-Faz D, Tolosa E (2009). Structural brain correlates of verbal fluency in Parkinson's disease. Neuroreport, 20:741-744.","DOI":"10.1097\/WNR.0b013e328329370b"},{"key":"key-10.14336\/AD.2024.0323-43","doi-asserted-by":"crossref","unstructured":"Camicioli R, Gee M, Bouchard TP, Fisher NJ, Hanstock CC, Emery DJ, et al. (2009). Voxel-based morphometry reveals extra-nigral atrophy patterns associated with dopamine refractory cognitive and motor impairment in parkinsonism. Parkinsonism & related disorders, 15:187-195.","DOI":"10.1016\/j.parkreldis.2008.05.002"},{"key":"key-10.14336\/AD.2024.0323-44","unstructured":"Ko JH, Spetsieris PG, Eidelberg D (2018). Network Structure and Function in Parkinson's Disease. Cereb Cortex, 28:4121-4135."},{"key":"key-10.14336\/AD.2024.0323-45","doi-asserted-by":"crossref","unstructured":"Gao Y, Nie K, Huang B, Mei M, Guo M, Xie S, et al. (2017). Changes of brain structure in Parkinson\u2019s disease patients with mild cognitive impairment analyzed via VBM technology. Neuroscience Letters, 658:121-132.","DOI":"10.1016\/j.neulet.2017.08.028"},{"key":"key-10.14336\/AD.2024.0323-46","doi-asserted-by":"crossref","unstructured":"Tremblay C, Abbasi N, Zeighami Y, Yau Y, Dadar M, Rahayel S, et al. (2020). Sex effects on brain structure in de novo Parkinson\u2019s disease: a multimodal neuroimaging study. Brain, 143:3052-3066.","DOI":"10.1093\/brain\/awaa234"},{"key":"key-10.14336\/AD.2024.0323-47","doi-asserted-by":"crossref","unstructured":"Dadar M, Gee M, Shuaib A, Duchesne S, Camicioli R (2020). Cognitive and motor correlates of grey and white matter pathology in Parkinson\u2019s disease. NeuroImage: Clinical, 27:102353.","DOI":"10.1016\/j.nicl.2020.102353"},{"key":"key-10.14336\/AD.2024.0323-48","doi-asserted-by":"crossref","unstructured":"Pereira JB, Ibarretxe-Bilbao N, Marti MJ, Compta Y, Junqu\u00e9 C, Bargallo N, et al. (2012). Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. Human brain mapping, 33:2521-2534.","DOI":"10.1002\/hbm.21378"},{"key":"key-10.14336\/AD.2024.0323-49","doi-asserted-by":"crossref","unstructured":"Hutton C, Draganski B, Ashburner J, Weiskopf N (2009). A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging. Neuroimage, 48:371-380.","DOI":"10.1016\/j.neuroimage.2009.06.043"},{"key":"key-10.14336\/AD.2024.0323-50","doi-asserted-by":"crossref","unstructured":"Pletcher C, Dabbs K, Barzgari A, Pozorski V, Haebig M, Wey S, et al. (2023). Cerebral cortical thickness and cognitive decline in Parkinson\u2019s disease. Cerebral Cortex Communications, 4:tgac044.","DOI":"10.1093\/texcom\/tgac044"},{"key":"key-10.14336\/AD.2024.0323-51","doi-asserted-by":"crossref","unstructured":"Devignes Q, Viard R, Betrouni N, Carey G, Kuchcinski G, Defebvre L, et al. (2021). Posterior cortical cognitive deficits are associated with structural brain alterations in mild cognitive impairment in Parkinson\u2019s disease. Frontiers in aging neuroscience, 13:668559.","DOI":"10.3389\/fnagi.2021.668559"},{"key":"key-10.14336\/AD.2024.0323-52","doi-asserted-by":"crossref","unstructured":"Chen F-X, Kang D-Z, Chen F-Y, Liu Y, Wu G, Li X, et al. (2016). Gray matter atrophy associated with mild cognitive impairment in Parkinson\u2019s disease. Neuroscience Letters, 617:160-165.","DOI":"10.1016\/j.neulet.2015.12.055"},{"key":"key-10.14336\/AD.2024.0323-53","doi-asserted-by":"crossref","unstructured":"Zheng D, Chen C, Song W, Yi Z, Zhao P, Zhong J, et al. (2019). Regional gray matter reductions associated with mild cognitive impairment in Parkinson's disease: A meta-analysis of voxel-based morphometry studies. Behav Brain Res, 371:111973.","DOI":"10.1016\/j.bbr.2019.111973"},{"key":"key-10.14336\/AD.2024.0323-54","doi-asserted-by":"crossref","unstructured":"Williams ME, Elman JA, Bell TR, Dale AM, Eyler LT, Fennema-Notestine C, et al. (2023). Higher cortical thickness\/volume in Alzheimer\u2019s-related regions: Protective factor or risk factor? Neurobiology of Aging.","DOI":"10.1002\/alz.078044"},{"key":"key-10.14336\/AD.2024.0323-55","doi-asserted-by":"crossref","unstructured":"Wyman-Chick KA, Martin PK, Weintraub D, Sperling SA, Erickson LO, Manning CA, et al. (2018). Selection of normative group affects rates of mild cognitive impairment in Parkinson's disease. Movement Disorders, 33:839-843.","DOI":"10.1002\/mds.27335"},{"key":"key-10.14336\/AD.2024.0323-56","doi-asserted-by":"crossref","unstructured":"Tulsky DS, Ledbetter MF (2000). Updating to the WAIS-III and WMS-III: Considerations for research and clinical practice. Psychological assessment, 12:253.","DOI":"10.1037\/\/1040-3590.12.3.253"},{"key":"key-10.14336\/AD.2024.0323-57","doi-asserted-by":"crossref","unstructured":"Brandt J (1991). The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms. The clinical neuropsychologist, 5:125-142.","DOI":"10.1080\/13854049108403297"},{"key":"key-10.14336\/AD.2024.0323-58","doi-asserted-by":"crossref","unstructured":"Benton AL, Varney NR, Hamsher Kd (1978). Visuospatial judgment: A clinical test. Archives of neurology, 35:364-367.","DOI":"10.1001\/archneur.1978.00500300038006"},{"key":"key-10.14336\/AD.2024.0323-59","doi-asserted-by":"crossref","unstructured":"Smith A (1973) Symbol digit modalities test: Western psychological services Los Angeles.","DOI":"10.1037\/t27513-000"},{"key":"key-10.14336\/AD.2024.0323-60","doi-asserted-by":"crossref","unstructured":"Kim N, Kim J-H, Wolters MK, MacPherson SE, Park JC (2019). Automatic scoring of semantic fluency. Frontiers in psychology, 10:1020.","DOI":"10.3389\/fpsyg.2019.01020"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T16:25:05Z","timestamp":1743783905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2024.0323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.14336\/ad.2024.0323","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}